Kornimate/medical-research-clean huggingface dataset:
preoperative chemoradiotherapy with gemcitabine for resectable pancreatic carcinoma

Conditions: Resectable Pancreatic Carcinoma

Summary: this phase ii study is to evaluate the efficacy of preoperative chemoradiotherapy with gemcitabine (400mg/m2, weekly) for resectable pancreatic cancer.

the primary objective of this study is to evaluate the complete (r0) resection rate for patients with and resectable pancreatic cancer treated with preoperative chemoradiotherapy and curative surgery. an experimental arm that result a complete resection rate of at least 90% would merit further study. with 90% power to reject that null hypothesis that the true complete resection rate is ≤75% with a type i error level of 5%, evaluable 53 patients are required. considering the 20% unevaluable patients due to the immediate distant metastasis after treatment7, 8, 17 and 10% follow up loss, a total of 64 eligible patients will be enrolled.

Eligibility criteria:
inclusion criteria: * patients with resectable pancreatic adenocarcinoma * age over 18 years old and younger than 70 year old * performance status (ecog scale): 0-1 * adequate organ functions * hb ≥9.0 g/dl * anc ≥1,500/mm3 * plt ≥100,000/mm3 * liver function: total bilirubin ≤3.0 mg/dl ast/alt/alp ≤3× upper limit of normal * creatinine ≤1.5 uln * patients should sign a written informed consent before study entry. exclusion criteria: * tumor type other than adenocarcinoma * unresectable for resection on preoperative evaluation * other primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin or prior malignancy treated more than 5 years ago without recurrence) * prior systemic therapy (for instance, cytotoxic chemotherapy or active/passive immunotherapy) * prior radiotherapy * major surgery within 4 weeks prior to study treatment * serious illness or medical conditions, as follows; * congestive heart failure (nyha class iii or iv) * unstable angina or myocardial infarction within the past 6 months, * significant arrhythmias requiring medication and conduction abnormality such as over 2nd degree av block * uncontrolled hypertension * hepatic cirrhosis( ≥ child class b) * interstitial pneumonia, pulmonary adenomatosis * psychiatric disorder that may interfere with and/or protocol compliance * unstable diabetes mellitus * uncontrolled ascites or pleural effusion * active infection * received any investigational drug or agent/procedure, i.e. participation in another trial within 4 weeks before beginning treatment with study drug * pregnant or lactating woman * women of child bearing potential not using a contraceptive method * sexually active fertile men not using effective birth control during medication of study drug and up to 6 months after completion of study drug if their partners are women of child-bearing potential * any patients judged by the investigator to be unfit to participate in the study

Keywords: preoperative chemoradiotherapy with gemcitabine
adult influenza vaccination text message reminders

Conditions: Influenza Vaccination

Summary: influenza infection leads to on average 24,0000 deaths and 150,000 hospitalizations annually. while vaccination is the cornerstone of preventing influenza infection, vaccination coverage in adults is low with only 35% vaccinated by end of november. latino adults have the lowest coverage rates. text message reminders have been used successfully for improving influenza vaccination for children. this study will assess the use of text messaging to improve influenza vaccination coverage rates in a largely minority, publicly insured adult population.


Eligibility criteria:
inclusion criteria: * \> or = 18 years of age, * at least one visit to the aim clinic during the previous year * a cell phone number in the registration system * fluent in english or spanish. exclusion criteria exclusion criteria: - receipt of influenza vaccination during the 2013-2014 influenza season prior to randomization.
efficacy of α-blocker or 5-ari withdrawal to continued combination therapy on the maintenance of luts in men with bph

Conditions: Prostatic Hyperplasia; Prostate Hyperplasia; Prostatic Hypertrophy

Summary: the investigators compare the efficacy of alpha-blocker and 5-ari withdrawal to continued combination therapy on the maintenance of luts and improvement of quality of life outcomes in men with benign prostatic hyperplasia.

benign prostatic hyperplasia (bph) is the primary cause of lower urinary tract symptoms (luts). combination therapy with an alpha-blocker and 5α reductase inhibitors (5-ari) is the first-line treatment of bph-related luts for the reduction of the size of the prostate and luts improvement. combination therapy is tolerated well by most men; however, the incidence of adverse events is higher than with either therapy alone. in patients with improved luts following combination therapy, the aim of this study is based on the hypothesis that the withdrawal of either therapy will not increase the risk of luts aggravation while improving the quality of life. the investigators plan a prospective, randomized, open-label, parallel trial, comparing alpha-blocker withdrawal and 5-ari withdrawal to continued combination therapy. treatments will be allocated in a 1:1:1 ratio, based on ipss score (≤30% decrease from baseline) and prostate volume (≤35% decrease from baseline).

Eligibility criteria:
inclusion criteria: * men aged ≥50 or \<80 years and * on combination therapy (alpha-blocker and 5-ari) ≥12 months and * ipss score (≤30% decrease from baseline) and * prostate volume (≤35% decrease from baseline) exclusion criteria: * suspected prostate cancer (psa density \>0.15 ng/ml/cc) requiring specific management * on-going prostatitis or urinary retention * acontractile detrusor * neurogenic lower urinary tract dysfunction * urethral stenosis * patient unable or unwilling to provide written informed consent

Keywords: alpha-blocker 5α reductase inhibitor withdrawal benign prostatic hyperplasia combination therapy
tirellizumab+anlotinib vs anlotinib for mss-type crc

Conditions: Colon Cancer; Immunotherapy

Summary: to compare the efficacy and safety of tirellizumab combined with anlotinib in the treatment of mss colorectal cancer. to investigate the effective biomarker of anlotinib combined with tiralizumab

this was a multicenter retrospective cohort study to compare the efficacy of tyrosine kinase inhibitor（tki） combined with immune checkpoint inhibitors(icis) versus tyrosine kinase inhibitor alone in the treatment of advanced mss colorectal cancer. patients with mss crc who have been confirmed by pathology and have relapsed or failed multiline therapy were included in the study. patients who had received tirellizumab plus anlotinib were considered the combination group, and those treated with anlotinib were classified as the monotherapy group. the efficacy and safety of the two regimens were compared. at the same time, whole-exome sequencing and transcriptome sequencing were performed on the patients in the response and non-response groups of the combination group to reveal the characteristics of their microenvironment and search for biomarkers related to response.

Eligibility criteria:
inclusion criteria: * 18-70 years old * patients with mss colorectal cancer who have been confirmed by pathology and have relapsed or failed multiline therapy * patients who have been treated with anlotinib monotherapy(12 mg qd, d1-14; 21 days per cycle) or anlotinib(12 mg qd, d1-14; 21 days per cycle)+ tislelizumab(200 mg, once every 3 weeks) * the presence of at least one measurable target lesion according to the response evaluation criteria in solid tumors (recist) version 1.1 exclusion criteria: * patients with other malignant tumors * prior treatment with antirotinib, anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137 or anti-ctla-4 antibodies or any other antibody or drug that specifically targets t cell co-stimulation or checkpoint pathways * follow-up was less than 30 days

Keywords: immunotherapy multi-omics analysis tirellizumab anlotinib
stampp-htn in a high-risk rural population of women

Conditions: Hypertension in Pregnancy

Summary: the purpose of this study is to determine if monitored blood pressure paired with education reduces maternal mortality and morbidity during the post-partum period in a high-risk rural population of women.

women with hypertension during pregnancy are at an increased risk of maternal mortality (death during or within 42 days of termination of pregnancy) and hypertension related morbidity. black women, women with lower education and less access to health care resources also have increased maternal mortality and morbidity. this project will use bluetooth enabled blood pressure devices to monitor blood pressure in a population of postpartum women at increased risk for maternal mortality and morbidity. we will compare the number of postpartum hypertensive incidences and severities to a population of women who did not have a postpartum blood pressure control intervention.

Eligibility criteria:
inclusion criteria: 1. signed informed consent in a postpartum woman between 18-45 years of age at the time of study enrollment 2. hospitalized for delivery with a hypertensive disorder of pregnancy as defined by acog 2019 guidelines (chronic hypertension, hellp syndrome, eclampsia, preeclampsia, gestational hypertension or new onset postpartum hypertension). 3. ability to understand english or spanish 4. reliable access to the internet and a bluetooth mobile device 5. willingness to download omron connect app and ability to use blood pressure monitor exclusion criteria: 1. does not meet inclusion criteria 2. postpartum or operative complication that prolongs hospital stay beyond postpartum day 10. 3. patients who are currently participating in another clinical trial to evaluate a therapeutic intervention for control of blood pressure.

Keywords: hypertension blood pressure post-partum telemonitoring
observational study of the long-term effect of latanoprost in normal tension glaucoma

Conditions: Low Tension Glaucoma

Summary: the purpose of this study is to assess the long-term efficacy and safety of latanoprost monotherapy in patients with normal tension glaucoma (ntg) using a prospective, observational design. visits were scheduled at 6-month intervals for 24 months. intraocular pressure (iop), optic nerve head findings, visual field status, and adverse events were recorded.


Eligibility criteria:
inclusion criteria: patients with normal-tension glaucoma exclusion criteria: none

Keywords: prospective non-interventional observational multi-center long-term
training of inhalation technique in hospitalized chronic obstructive pulmonary disease (copd) patients - a pilot study

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: inhalation drugs are essential in the treatment of copd, in controlling symptoms and preventing exacerbations. the aim of this pilot study is to collect data necessary for the planning of future efficacy trials. we plan to assess the value of providing training in inhalation technique to hospitalized copd patients. data on rehospitalizations will be collected from the hospital's medical records and from the national patient registry . the inhalation technique of all recruited patients will de assessed at baseline. the patients will then be randomised 1:1 to the intervention or standard care group. the intervention consists of a drug counselling, focusing on inhalation technique. in addition patients in the intervention group will have their medicines personally delivered from the hospital pharmacy at discharge (discharge service). patients will be asked to fill in questionnaires evaluating the inhalation training and the discharge service


Eligibility criteria:
inclusion criteria: * patients admitted to the pulmonary ward, the medical department, oslo university hospital, oslo, norway exclusion criteria: patients * previously included to the study * usually not administering their inhalation drugs themselves * using nebulizer chamber with their drug * who are contagious, thus restricting accessibility of personnel * who are not able to provide informed consent
exercise prior to allogeneic hematologic stem cell transplantation

Conditions: Allogeneic Stem Cell Transplantation

Summary: the investigators hypothesize that inactivity during the search for a donor may exacerbate current deconditioned states; subsequently, influencing risk factors for post-transplant complications that hinder the recovery phase. this study is designed to investigate if exercise therapy administered prior to allogeneic hematologic stem cell transplantation (hsct) can influence physical and psychological side-effects associated with hsct. approximately 6-weeks prior to hsct, individuals will be randomized into either an exercise group or usual care group and followed until one year after hsct.


Eligibility criteria:
inclusion criteria: * medical indication: allogeneic stem cell transplantation at princess margaret hospital * must be ambulatory without need for human assistance at time of recruitment * medically cleared to exercise by the transplant physician * demonstrates willingness to attend supervised sessions * sufficient in english to ensure safety of understanding prescribed exercise guidelines, or has access to an adequate non-familial interpreter exclusion criteria: * another active malignancy * less than 4 weeks till the scheduled hsct * refusal to be randomized * does not have the approval of their transplant physician * severe or unstable neurological, cardiorespiratory, musculoskeletal disease or mental illness

Keywords: exercise quality of life fatigue symptoms prehabilitation aerobic capacity
neurobiological predictors of huntington's disease (predict-hd)

Conditions: Huntington Disease

Summary: the purpose of this trial is to study early brain and behavioral changes in people who have the gene expansion for huntington's disease, but are currently healthy and have no symptoms.

huntington's disease (hd) is an inherited disease that causes changes in a person's ability to control movements, thinking, and feelings. the intent of this study is to learn more about the beginning changes in thinking skills, emotional regulation, and brain structure and function as a person begins the transition from health to hd. preliminary studies indicate that people with hd may have marked decline before an actual diagnosis. this study will help reveal the earliest indicators of the disease and what factors influence the age at which a person carrying the gene develops the disease. it is necessary to get information on the early stages of hd in order to develop drugs that can slow or postpone the onset of hd. the investigators hope this study will provide essential information for future trials of experimental drugs for hd. during this study, participants will undergo several detailed tests, including mri scans of the brain, cognitive assessments, physical exams, bio specimen (blood, urine, cerebral spinal fluid) collection and neurological and psychiatric testing.

Eligibility criteria:
inclusion criteria: * men and women at risk for hd, who have been tested for the hd gene mutation, and who have not been diagnosed with symptoms of hd (cag ≥36 for cag-expanded group or cag \<36 for cag-norm group). exclusion criteria: * diagnosis of manifest hd (at least 50% confidence by neurologist that symptoms are present); * clinical evidence of unstable medical or psychiatric illness (including substance abuse); * history of sever learning disability or mental retardation; * history of other cns disease or event (e.g., seizures or head trauma); * current treatment with antipsychotic medications, including the traditional neuroleptics such as haloperidol as well as the atypical antipsychotics risperidone, clozapine, quetiapine, and olanzapine; * treatment with phenothiazine-derivative antiemetic medications such as prochlorperazine, metoclopramide, promethazine, and inapsine on a regular basis (greater than 3 times per month); specific exclusion criteria for the lumbar puncture: * current use of anti-coagulants * current use of anti-platelets * unable to provide consent for him/herself

Keywords: huntington's disease huntington disease hd
nitazoxanide plus lactulose versus lactulose alone treatment of hepatic encephalopathy

Conditions: Encephalopathy, Hepatic

Summary: hepatic encephalopathy (he) is a reversible neuropsychiatric syndrome associated with chronic and acute liver dysfunction. it is characterized by cognitive and motor deficits of varying severity. treatment options include lactulose administered orally or by nasogastric tube or enema, non-absorbable antibiotics, and protein-restricted diets. nitazoxanide is an oral agent indicated for the treatment of infectious diarrhea caused by crytpsporidiumparvum and giardia lamblia. basu and colleagues presented a pilot prospective study at the 2008 american association for the study of liver diseases meeting showing clinical improvement in he among cirrhotic patients who received nitazoxanide and lactulose.

hepatic encephalopathy (he) is a reversible neuropsychiatric syndrome associated with chronic and acute liver dysfunction. it is characterized by cognitive and motor deficits of varying severity. hepatic encephalopathy is caused by accumulation of nitrogenous substances, primarily ammonia, in the blood. in advanced stages it is referred to as hepatic coma which may be preceded by seizures. the treatment goal is to reduce nitrogen load from the gi tract and to improve central nervous system (cns) status. treatment options include lactulose administered orally or by nasogastric tube or enema, non-absorbable antibiotics, and protein-restricted diets. lactulose is nonabsorbable disaccharides that are currently used as first line agents for the treatment of he. its action is thought to beconversion to lactic acid and acetic acid resulting in acidification of the gut lumen. this favors conversion of ammonia (nh3) to ammonium (nh4+), which is relatively membrane impermeable, and inhibits ammoniagenic coliform bacteria. nitazoxanide is an oral agent indicated for the treatment of infectious diarrhea caused by crytpsporidiumparvum and giardia lamblia. basu and colleagues presented a pilot prospective study at the 2008 american association for the study of liver diseases meeting showing clinical improvement in he among cirrhotic patients who received nitazoxanide and lactulose. mantry and colleagues showed that the number of hospitalizations and the duration of hospital stays were shortened for patients receiving combination therapy compared with those receiving lactulose monotherapy.

Eligibility criteria:
inclusion criteria: age 18-70 years cirrhosis, defined by a combination of any of the following: * laboratory findings * endoscopic results * ultrasound * histology overt hepatic encephalopathy exclusion criteria: * • creatinine\>1.5 mg/dl * alcohol use within prior 4 weeks * non-hepatic metabolic encephalopathy * hepatocellular carcinoma * degenerative cns disease * any significant psychiatric illness or other medical comorbidity
a study of the efficacy and safety of pregabalin as add-on therapy for partial onset seizures in children ages 4-16 years

Conditions: Epilepsy, Partial Seizures

Summary: study a0081041 is a double blind, placebo controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of two dose levels of pregabalin administered in equally divided daily doses, in either capsule or oral liquid formulation, as adjunctive therapy in pediatric subjects 4 to 16 years of age with partial onset seizures.


Eligibility criteria:
inclusion criteria: * subjects and/or parent(s)/legally acceptable representative must be considered willing and able to sign consent, and complete daily seizure diaries and monitor seizure frequency. * male and female epilepsy subjects, 4 to 16 years of age inclusive on the date of the screening visit. * diagnosis of epilepsy with partial onset seizures classified as simple partial, complex partial or partial becoming secondarily generalized, according to the international league against epilepsy (ilae) diagnosis criteria. * must have a partial onset seizure frequency of at least 3 seizures per 28 day period prior to screening. must have a partial onset seizure frequency of at least 6 seizures and no continuous 4 week seizure free period during the 8 week baseline phase prior to randomization. * currently receiving a stable dose of 1 to 3 antiepileptic drugs (stable within 28 days prior to screening). exclusion criteria: * primary generalized seizures (including in the setting of co-existing partial onset seizures) which include, for example: clonic, tonic and clonic-tonic seizures (note that partial onset seizures that become secondarily generalized are not exclusionary); absence seizures; infantile spasms; myoclonic, myoclonic atonic, myoclonic tonic seizures. * lennox gastaut syndrome, benign epilepsy with centrotemporal spikes (bects) and dravet syndrome. * a current diagnosis of febrile seizures, or seizures related to an ongoing acute medical illness. any febrile seizures within 1 year of screening. * status epilepticus within 1 year prior to screening. * seizures related to drugs, alcohol, or acute medical illness. * any change in aed regimen (type of medication or dose) within 28 days of the screening visit or during the baseline phase. * progressive structural cns lesion or a progressive encephalopathy.

Keywords: safety efficacy partial onset seizures pediatric pregabalin placebo-controlled double-blind
pharmacist-intensivist collaborative telehealth for post-intensive care syndrome

Conditions: Post Intensive Care Syndrome (PICS)

Summary: the goal of this pilot randomized controlled trial is to determine if a randomized controlled trial of a collaborative pharmacist-intensivist telehealth follow-up after intensive care unit discharge can feasibly be performed in patients who have survived a critical illness. the study intervention will be telehealth follow-up appointments provided by clinical pharmacists at approximately one and three months post-hospital discharge. the purpose of the follow-up appointments will be to assess for post-intensive care syndrome and provide recommend interventions aimed at improving recovery participants will randomized to receive the study intervention or standard of care.


Eligibility criteria:
inclusion criteria: * adults 18-89 years of age * required admission to either medical or surgical icu * respiratory failure requiring invasive mechanical ventilation of at least 24 hours during icu stay; or icu stay of at least 7 days * anticipated discharge to home after hospitalization * consent from patients themselves or a legally authorized representative if necessary exclusion criteria: * pregnancy * incarceration/imprisonment * life expectancy less than 6 months or enrolled in hospice/palliative care * anticipated discharge to skilled nursing facility, medical rehabilitation facility, or other long terms care facility * unable to participate in telehealth
af at home: a virtual education program for patients with atrial fibrillation (af)

Conditions: Atrial Fibrillation

Summary: the goal of this study is to determine the effectiveness of a direct-to-patient virtual education program ("af at home") for adults with atrial fibrillation (af). the main questions this study aims to answer are: 1. will participants in the educational program have improvement in quality of life, self-monitoring, and self-management strategies after program completion? 2. will patient level quality of af care improve for participants in the educational program? participants will be asked to: * participate in six hours of virtual education sessions over three weeks via zoom. * complete online questionnaires before the program starts and after its completion.


Eligibility criteria:
inclusion criteria: * patient with diagnosis of non-valvular or valvular atrial fibrillation * age \>/= 18 exclusion criteria: * unable to provide informed consent * incarcerated patient